

NEW HAMPSHIRE BOARD OF PHARMACY

PUBLIC MINUTES (04/15/15)

MEETING CALLED TO ORDER AT 9:24 AM

CHARLES FANARAS, PRESIDENT PRESIDING

MEMBERS PRESENT:

MICHAEL BULLEK
CHARLES FANARAS
JOHN GENOVESE

HELEN PERVANAS
GARY MERCHANT
ROBERT STOUT

1—MINUTES FROM PUBLIC MEETING 3/18/15:

MOTION TO ACCEPT: Motion: GENOVESE SECOND: MERCHANT VOTE: 4-0-2 (BULLEK AND PERVANAS
ABSTAINED)

2—PUBLIC HEARING ON Ph 700 RULES

The board received both printed and verbal testimony on the Ph 700 rules regarding the standards of practice. We received comments and questions on the proposed PIC exam. The board clarified this exam would be available with appointments and could be taken in advance of a pharmacist being selected to serve as a PIC. Many commented on the documentation of the mandatory counselling and how many systems did not have the ability to document the kind of detail the rule required. The board will review other options. Also on the mandatory counselling area there was concern brought over the ability to counsel patients not present, such as assisted living, nursing home, prisons, etc. The board will look at this section as well as the drugs involved. Public comment was closed at 12:00PM.

3—COMPLIANCE REPORT- MARGARET CLIFFORD-CCI

CCI Clifford presented her report. Went over the number as they were down slightly but included in the report were a number of sterile compounding facilities which take significantly more time and resources.

MOTION TO ACCEPT COMPLIANCE REPORT:

MOTION: GENOVESE SECOND: BULLEK VOTE: 6-0

4---PMP MONTHLY REPORT: MICHELLE RICCO JONAS:

MOTION TO ACCEPT PMP REPORT:

MOTION: BULLEK SECOND: MERCHANT VOTE: 6-0

5—WENTWORTH DOUGLAS OUTPATIENT PHARMACY; CHANGE OF LOCATION/NAME

MOTION TO APPROVE LICENSE:

MOTION: PERVANAS

SECOND: BULLEK

VOTE: 6-0

6—NH EMS MEDICATION FORMULARY; DR JIM SUOZZI

Dr. Suozzi was requesting the Board authorize the expansion of the EMS formulary to include the following: Dexamethasone, prednisone po, calcium gluconate IV and hydromorphone injectable.

MOTION WAS MADE TO APPROVE THIS FORMULARY EXPANSION AFTER RECEIPT OF A FORMAL LETTER REQUESTING THESE ADDITIONS

MOTION: BULLEK

SECOND: GENOVESE

VOTE: 6-0

7—VOTE NEEDED TO ADOPT BOTH RULE Ph 400 and Ph 401.02 & 1303.02

MOTION TO ADOPT Ph 400:

MOTION: GENOVESE

SECOND: BULLEK

VOTE: 6-0

MOTION TO ADOPT Ph 401.02 and Ph 1303.02

MOTION: BULLEK

SECOND: GENOVESE

VOTE: 6-0

8—REVIEW OF PHARMACIST RECIPROCITY APPLICATION WITH DISCIPLINE - MILLICENT DEYA;

The Board reviewed the application of Ms. Deya and was concerned over her inability to truthfully complete the application by not reporting the discipline that she had received from another state. The NH Board has shown no tolerance to applicants who do not truthfully answer questions and supply honest information.

MOTION TO DENY LICENSE BASED ON RSA 318:29, II (a).

MOTION: PERVANAS

SECOND: BULLEK

VOTE: 6-0

9—PHONG LY PHARMACIST RECIPROCITY WITH DISCIPLINE;

MOTION TO APPROVE:

MOTION: BULLEK

SECOND: GENOVESE

VOTE: 6-0

10—WILLIAM STUART-PHARMACIST RECIPROCITY WITH DISCIPLINE;

MOTION TO APPROVE: MOTION: BULLEK

SECOND: GENOVESE

VOTE: 6-0

11—ALYSSA BOUTIN—REVIEW OF PHARMACY INTERN APPLICATION;

MOTION TO APPROVE:

MOTION: BULLEK

SECOND: PERVANAS

VOTE: 6-0

12—ANNIE WASHBURN, PHARMACY TECH WITH DISCIPLINE;

MOTION TO APPROVE:

MOTION: GENOVESE

SECOND: BULLEK VOTE: 4-2 (FANARAS/MERCHANT)

SECONDARY MOTION TO ISSUE LETTER OF CONCERN TO MS WASHBURN:

MOTION: MERCHANT

SECOND: PERVANAS

VOTE: 6-0

13—TRICARE COVERAGE FOR OTC PRODUCTS;

REQUEST COMPLIANCE FIND OUT HOW THE BILLING PROCESS IS DONE; DO THEY MAKE RX OR JUST TRANSMIT THE DATA ON ITEM?

14 – NH HOSTED NABP/AACP DISTRICT I MEETING

DISCUSSION ONLY – NO MOTION/VOTE NECESSARY OR TAKEN.

15—DISCUSSION OF LICENSING 3PL'S BASED ON NEW FEDERAL DRUG SUPPLY SECURITY ACT

CCI CLIFFORD WILL UPDATE BOARD AFTER REVIEWING FDA POSITION IN MAY

16—REVIEW OF RENEWAL APPLICATIONS FOR MANUFACTURERS/WHOLESALERS

Board discussed and directed Jason Richard to modify the application by having separate check boxes on exactly what function the licensee is partaking in.

17—PUBLIC HEALTH CLINICS APPLICATION;

Directed to leave as is.

18—METHADONE CLINIC APPLICATION;

Directed to leave as is.

19—MEDICAL GAS/DEVICE DISTRIBUTOR

Directed to leave as is. Board will work on developing a rules section for this practice.

20—BOARD DISCUSSED THE LIST OF NR PHARMACIES UNDER REVIEW;

IN AN EFFORT TO GIVE GUIDANCE TO LICENSING THE BOARD VOTED ON THE FOLLOWING:

MOTION TO DENY ANY APPLICANT WHO ATTESTS TO BE A 503b FROM ATTAINING A nr LICENSE WHICH IS DESIGNED FOR 503A FACILITIES:

MOTION: STOUT SECOND: BULLEK VOTE: 6-0

MOTION TO GIVE GUIDANCE TO APPLICANTS THAT DO NOT HAVE INSPECTION REPORTS WITH THEIR APPLICATIONS THAT THEY HAVE 30 DAYS TO SUBMIT AN INSPECTION REPORT OR WITHDRAW THEIR APPLICATION OR THEIR REQUEST FOR RENEWAL/NEW PERMIT WILL BE DENIED.

MOTION: BULLEK SECOND: GENOVESE VOTE: 6-0

MOTION TO DENY NE HOME THERAPIES:

MOTION: BULLEK SECOND: PERVANAS VOTE: 6-0

MOTION TO ADJOURN THE MEETING:

MOTION: BULLEK SECOND: GENOVESE VOTE: 6-0

MEETING ENDED 2:25PM

Respectfully,

Robert J. Stout, RPh
Vice President
Board of Pharmacy